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Purpose/Objective: Volumetric-modulated arc therapy (VMAT) is a 
novel form of intensity-modulated radiotherapy (IMRT) optimization 
which can provide better organ at risk sparing. The aim of the study 
was to check testicular doses distribution from VMAT in localized 
prostate cancer patients (pts). 
Materials and Methods: Based on computed tomography data sets of 5 
prostate cancer pts the Monacosystem (Monte Carlo algorithm) for 
VMAT was used to calculate testes dose from small field prostate 
irradiation. The dose from X-ray volume imaging performed during 
1st, 2nd, 3rd and every 7th fractions of radiotherapy was measured 
using diagnostic dosemeter DIADOS E (PTW) with semiconductor 
detector. Mean volume of testes and PTV was 77,4 and 205 cm3, 
respectively. Total dose of radiotherapy was 76Gy (photon 6-MV 
energy, 38 fractions).  
Results: The VMAT delivered a mean testicular dose of 49 cGy. The 
maximum dose was 140 cGy, the minimum – 0.0 cGy. The mean and 
maximum testicular dose did not correlate with volume of PTV in 
VMAT procedure (r =0,12). From X-ray volume-imaging the testes 
received additional dose of 3,6 mGy from one scan (mean total dose – 
37,6 mGy).  
Conclusions: VMAT provides quite good testes sparing that is why it 
should be a method of choice in radiotherapy of younger prostate 
cancer patients. Even with daily X-ray imaging radiotherapy the dose 
to the testes is acceptable.  
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Purpose/Objective: The benefit of radiation therapy on local lymph 
nodes to reduce local recurrence, from cancers such as breast and 
rectum, is well documented. After radical prostatectomy the most 
important high-risk pathologic features are: extra capsular extension 
(ECE), positive margins (R+) and seminal vesicle involvement (SVI). 
Patients with these adverse features have an increased risk of 
biochemical failure of about 40-50%. In these cases the appropriate 
treatment is radiotherapy, otherwise there are some controversies 
about the real benefit of Whole Pelvis Radiation Therapy (WPRT). The 
purpose of our work is to provide our experience on the decision 
criteria about WPRT. 
Materials and Methods: From 2007 to 2012 we have treated 676 
consecutive patients with diagnosis of prostate cancer. 219 patients 
underwent radical prostatectomy and were enrolled for adjuvant 
radiotherapy because of the presence of one of the following 
pathologic features: ECE, positive margins or SVI. We have also 
divided the patients according to the type of lymph node dissection 
performed in Extended, Limited and Minimal (ELD, LLD and MLD). 45 
patients underwent whole pelvis irradiation and subsequent boost on 
prostate bed. CTV was delineated to encompass the distal common 
iliac, internal iliac, and external iliac nodes. The total dose to the 
pelvis was 45 Gy in 1.8 Gy/Fr , while for prostate bed boost the 
minimum dose prescribed was 70.2 Gy, ( 77 Gy to macroscopic 
residual).  
Results: In our department most of the patients eligible for post-
prostatectomy radiotherapy does not received WPRT ( 174 Pts. 79.4%) 
and 20.6 % received it ( 45 Pts.). The extended lymph node dissection 
(ELD) have demonstrated high rate of lymph node metastases outside 
the area normally encompassed by standard lymph node dissection 
and in a recent review nomograms and equations have been 
questioned regarding their utility to predict nodes involvement. 
Therefore, in our experience is given a lot of importance to the extent 
of lymphadenectomy, which is the key point in the decision tree. As 
reported in the literature no increase in late toxicity was observed in 
the group WPRT but a slightly higher acute grade 3 small bowel and 
rectal toxicity. 
Conclusions: We consider useful WPRT after radical prostatectomy in 
selected high and intermediate risk patients, probably the indications 
for use of this technique will widen, however, is necessary a better 
identification of the subset of patients that really can benefit from 
WPRT. To date the results of the most important studies are not 
conclusive and WPRT remain an argument of debate. Since the end of 
2012 we started to implement the IMRT technique with a view to 
expanding the indications for WPRT based on the type of lymph node 
dissection performed and risk factors present prior to surgery.  
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Purpose/Objective: Diethylstilbestrol (DES) administration was a 
classic form of androgen deprivation therapy (ADT). Despite its 
comparable efficacy to orchiectomy in advanced prostate cancer, its 
use as first line treatment declined due to thromboembolic side 
effects and the emergence of novel therapeutic agents with a superior 
safety profile. We report our experience with DES in patients failing 
androgen suppression either with single agent or combined androgen 
blockage. 
Materials and Methods: A total of 67 patients with a median age of 69 
years (range 48-89) with advanced or metastatic prostate cancer were 
treated with DES between January 2009 to May 2012 after failing 
androgen suppression, either with LHRH analogues, anti-androgens or 
combined androgen blockage. 77% patients had metastatic and 23% 
patients had locally advanced disease. Median number of previous 
hormonal maneuvers used was 2 (range 1-6) and median time since 
initial hormonal treatment was 7 months (range 1-66). Median pre-DES 
PSA was 90ng/ml (range 4.9-4451). DES at a dose of 2.5mg PO plus low 
dose aspirin 75 mg PO was given for thrombosis prophylaxis. Patients 
with a history of ischemic heart disease, stroke, pulmonary embolism 
(PE) or thrombosis were not offered DES.  
Results: Median treatment duration was 4.5 months. 54% of patients 
responded to DES and among responders, 60% of patients had PSA 
response of more than 50% compared to baseline. Median time to 
biochemical progression was 4 months (range 1-47). Complications 
included; deep vein thrombosis in 3%, myocardial infarction in 3% and 
gynecomastia in 5% of patients.  
Conclusions: DES can give useful palliative responses after failure of 
standard hormonal therapy for modest duration. Cardiovascular 
complications still persist, requiring the development of safe, 
effective antithrombotic therapy to take advantage of this drug. 
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Purpose/Objective: Hypofractionated radiotherapy is a promising 
concept in the treatment of localized prostate cancer. Accurate dose 
volume thresholds for organs-at-risk are unknown in this setting. 
However, it is well known that acute toxicity is often a predictor for 
late rectal or bladder toxicity. We report treatment tolerance and 
acute toxicity during hypofractionated radiotherapy using image-
guided intensity modulated radiation therapy (IG-IMRT) for localized 
prostate cancer from a single centre in India and attempt to identify 
dose-volume correlates. 
Materials and Methods: Forty patients with localized prostate cancer 
were treated with IG- IMRT between July 2011 and Sep 2012. Two 
dose fractionation schedules were used (n=18 received 65Gy/25Fr/5 
weeks; and n=22 received 60Gy/20Fr/4weeks).The majority of 
patients (73.5%) had high-risk localized disease and received elective 
pelvic radiotherapy to a dose of 45Gy/25Fr or 44Gy/20Fr using a single 
phase plan. Uniform PTV margins of 7mm were used around the 
prostate ±seminal vesicles. The rectum and bladder were contoured as 
whole organs. Treatment was planned on Varian Eclipse® and 
TomoTherapy HiArt® platforms. Patients were assessed weekly for 
acute toxicity using the RTOG acute toxicity criteria during and up to 
6 weeks after treatment.  
Results: The treatment was well tolerated and all patients completed 
their scheduled course. There was no acute grade (Gr) 3 or 4 
gastrointestinal(GI) or genitourinary (GU) toxicity. The incidence of 
maximal acute rectal toxicity was Gr 2 22.5% and Gr 1 47.5%. The 
incidence of maximal GU toxicity was Gr 2 10% and Gr 1 52.5%. Small 
bowel toxicity was negligible (Gr 1 12.5%). There was no difference in 
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fractionation schedules. When 2 Gy equivalent doses to the rectum or 
bladder (EQD2 assuming rectal/bladder a/b=3) were compared 
between those suffering from Gr 2 toxicity or less, we found absolute 
dose-volumes to be better predictors than relative dose-volumes. 
Those with Gr 2 GI toxicity had a significantly higher V50GyEQD2 (29.7cc 
vs. 17.8cc, p=0.01) and V60GyEQD2 (27.6cc vs. 18.4cc, p=0.04). Higher 
dose volumes were not different. Those with Gr 2 GU toxicity had a 
significantly higher V70GyEQD2 (36.6cc vs. 18.7cc, p=0.004) and 
V65GyEQD2 (36.8cc vs. 19.0cc, p =0.004). ROC curve analysis showed 
that V50GyEQD2> 17.3cc and V60GyEQD2 > 9.8cc were best thresholds for 
Gr 2 GI toxicity.Reliable threshold estimates were not obtained for GU 
toxicity due to small numbers with Gr 2 toxicity. 
Conclusions: Moderate hypofractionation with IG-IMRT is well-
tolerated, even with elective pelvic irradiation. Dosimetric 
correlations indicate that certain absolute dose-volume parameters 
may be useful in predicting acute toxicity with these fractionation 
schedules. 
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Purpose/Objective: Adjuvant radiotherapy after prostatectomy for 
prostate cancer has not increased enough compared to salvage 
radiotherapy in Japan. We retrospectively evaluated the outcome in 
patients receiving adjuvant radiotherapy and prognostic factors in 
Japan.  
Materials and Methods: Between 2005 and 2008, a total of 91 patients 
were referred for adjuvant radiotherapy in 23 institutions. Median 
age: 64 years (53-78 years), Median i-PSA: 11.8ng/ml (4.8-280ng/ml). 
Gleason score (GS):6 /7 /8 /9 /10 =6.6% / 37.8%/ 22.2%/ 26.7%/0%. 
Positive rates of marginal status, seminal vesicle invasion (SVI) and 
Extra-prostatic extension (EPE) were 73.3%, 28.9%, 65.6%, 
respectively. Median postoperative PSA nadir: 0.18ng/ml 
(0~2.51ng/ml). Median time from surgery to radiotherapy was 3 
months (1~12 months). A total dose of 60-65Gy was administered in 
65.6% of patients. 
Results: Median follow-up was 62 months. The 3- and 5-years bRFS 
rate for all patients were 65.6% and 56.5%, respectively. A statistically 
significant relationship existed between GS and marginal status 
(p=0.019), GS and SV (p=0.001), marginal status and EPE (p=0.017), 
type of hormonal therapy and total dose (p=0.026). The 5-year bRFS in 
patients with SV negative was 65.1% compared to 35.8% with SV 
positive (p=0.001). The 5-year bRFS in postoperative PSA nadir?0.2 
was significantly higher than postoperative PSA nadir>0.2 (68.3% vs. 
43.6%, p=0.02). The 5-year bRFS in patients who were given 
radiotherapy ?3 months from surgery tended to be more favorable 
than >3 months (p=0.069). On multivariate analysis, SV invasion and 
postoperative PSA nadir were independent prognostic factors for a 
reduced bRFS (p=0.001 and 0.018, respectively). Age, i-PSA, GS, 
marginal status, EPE, hormonal therapy and total dose were no longer 
an independent prognostic factors. 
Conclusions: The 3- and 5-years bRFS rate for all patients were 65.6% 
and 56.5%, respectively. SV invasion and postoperative PSA nadir were 
most significant prognostic factors.  
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Purpose/Objective: Cone beam CT (CBCT) images can be captured 
during delivery of VMAT rotational radiotherapy. The quality of 
simultaneous CBCT’s is affected by scatter from the megavoltage 
beam and artefact from other factors such as bowel gas. We 
developed, verified and used a novel scoring system to rate the 
quality and clinical usefulness of simultaneous CBCT’s captured during 
prostate radiotherapy. 
Materials and Methods: A novel three point scoring system was 
developed to score the quality of CBCT scans; this reflected whether 
CBCT’s were of sufficient quality to be used in clinical practice to 
verify the position of the prostate. Two oncologists and three 
radiographers each scored 25 CBCT’s in order to validate the scoring 
system. To assess intra-observer variability, each observer re-scored 5 
of the previously assessed CBCT’s. Fifteen patients with localised 
prostate cancer were treated with radical VMAT radiotherapy. 
Treatment was delivered using a single 8 MV arc on an Elekta linear 
accelerator fitted with a Synergy CBCT system. Standard and 
simultaneous CBCT’s were captured on fractions 1, 6, 11 and 16. The 
simultaneous CBCT data was reconstructed and image quality was 
improved using in-house software. Using the validated scoring system, 
2 observers scored 120 CBCT’s collected during treatment of the 15 
patients; 60 scans were standard CBCT’s and 60 were corrected 
simultaneous CBCT’s (csCBCT). 
Results: During the validation exercise, inter-observer variability was 
low; Fleiss’ kappa statistic 0.796. There was greatest agreement 
regarding the best quality scans; kappa statistic 0.910. Intra-observer 
variability was also low; mean kappa statistic 0.82 (range 0.67-1.00).  
During the second scoring exercise, observer 1 rated 60 (100%) 
standard CBCT’s and 40 (67%) csCBCT’s to be clinically useful. 
Observer 2 rated 58 (97%) standard CBCT’s and 49 (82%) csCBCT’s to 
be clinically useful. The two observers agreed that 36 (60%) csCBCT’s 
were of sufficient quality to be useful for clinical decision making. 
Further results of how each observer rated the quality of the CBCT’s 
are given in table 1. 
 







(Not clinically useful) 
0 20 
(33%) 





25 (42%) 37 
(62%) 




35 (58%) 3 (5%) 44 (73%) 4 (7%) 
 
Table 1. Results of scoring exercise for 60 standard CBCT's and 60 
corrected simultaneous CBCT's (csCBCT) 
Conclusions: Simultaneous CBCT identifies the position of the 
prostate during treatment delivery and removes the uncertainty of 
prostate motion in the interval between standard CBCT and 
treatment. This provides a more accurate assessment of target 
coverage during treatment. Simultaneous scanning also reduces the 
time the patient is on the treatment couch. The quality of 
simultaneous CBCT’s is degraded by megavoltage scatter and artefact. 
Despite this, simultaneous CBCT scanning can produce images which 
are of sufficient quality to be used for clinical decision making. 
Further development and refinement of this technique is warranted. 
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Purpose/Objective: Some patients with localised prostate cancer 
treated with SBRT have been noted to experience short-lived but 
troublesome genitourinary symptoms consisting of frequency and 
dysuria associated with a marked rise in the International Prostate 
Symptom Score (IPSS). Gastrointestinal symptoms have not been 
frequent. We investigated potential patient specific and dosimetric 
parameters that may predict for this syndrome and to suggest 
selection criteria that may reduce the incidence.  
Materials and Methods: Eighteen consecutive patients undergoing 
prostate SBRT at our institution for organ-confined prostate cancer 
had IPSS toxicity recorded at baseline and then every 2 weeks for 12 
weeks after the commencement of SBRT. The maximal recorded IPSS 
was tested against various patient parameters (prostate volume, 
bladder volume and separation at the level of the prostate) and 
features of the radiotherapy plan including bladder and urethral DVH 
parameters used in clinical practice. Patients were not catheterised 
